-
EP2828295
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP2828295
| EP2828295 - ANTI-IL-1BETA AGENT FOR USE IN THE TREATMENT OR THE PREVENTION OF AORTIC ANEURYSM [Right-click to bookmark this link] | |||
| Former [2015/05] | METHOD AND PHARMACEUTICAL COMPOSITION FOR USE IN THE TREATMENT OR THE PREVENTION OF ANEURYSM | ||
| [2017/36] | Status | The application is deemed to be withdrawn Status updated on 29.06.2018 Database last updated on 19.10.2024 | |
| Former | Grant of patent is intended Status updated on 21.09.2017 | ||
| Former | Examination is in progress Status updated on 11.01.2017 | Most recent event Tooltip | 29.06.2018 | Application deemed to be withdrawn | published on 01.08.2018 [2018/31] | Applicant(s) | For all designated states INSERM (Institut National de la Santé et de la Recherche Médicale) 101, rue de Tolbiac 75013 Paris / FR | For all designated states Université Paris Descartes 12, rue de l'Ecole de Médecine 75006 Paris / FR | [2017/42] |
| Former [2015/05] | For all designated states INSERM - Institut National de la Santé et de la Recherche Médicale 101, rue de Tolbiac 75013 Paris / FR | ||
| For all designated states Université Paris Descartes 12, rue de l'Ecole de Médecine 75006 Paris / FR | Inventor(s) | 01 /
MALLAT, Ziad U970 PARCC GH Georges Pompidou Broussais 56 rue Leblanc 75015 Paris / FR | 02 /
TALEB, Soraya U970 PARCC GH Georges Pompidou Broussais 56 rue Leblanc 75015 Paris / FR | 03 /
TEDGUI, Alain U970 PARCC GH Georges Pompidou Broussais 56 rue Leblanc 75015 Paris / FR | [N/P] |
| Former [2015/05] | 01 /
MALLAT, Ziad U970 Parcc GH Georges Pompidou Broussais 56 rue Leblanc F-75015 Paris / FR | ||
| 02 /
TALEB, Soraya U970 Parcc GH Georges Pompidou Broussais 56 rue Leblanc F-75015 Paris / FR | |||
| 03 /
TEDGUI, Alain U970 Parcc GH Georges Pompidou Broussais 56 rue Leblanc F-75015 Paris / FR | Representative(s) | Hirsch, Denise Marie Inserm Transfert IP Department 7 rue Watt 75013 Paris / FR | [2015/05] | Application number, filing date | 13709446.2 | 15.03.2013 | WO2013EP55385 | Priority number, date | EP20120305323 | 19.03.2012 Original published format: EP 12305323 | [2015/05] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2013139701 | Date: | 26.09.2013 | Language: | EN | [2013/39] | Type: | A1 Application with search report | No.: | EP2828295 | Date: | 28.01.2015 | Language: | EN | The application published by WIPO in one of the EPO official languages on 26.09.2013 takes the place of the publication of the European patent application. | [2015/05] | Search report(s) | International search report - published on: | EP | 26.09.2013 | Classification | IPC: | C07K16/24, A61P9/00 | [2015/05] | CPC: |
C07K16/245 (EP,US);
A61K38/2006 (EP,US);
A61P43/00 (EP);
A61P9/00 (EP);
A61P9/14 (EP);
A61K2039/505 (EP,US);
C07K2317/76 (EP,US)
(-)
| Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2015/05] | Title | German: | ANTI-IL-1BETA MITTEL ZUR VERWENDUNG BEI DER BEHANDLUNG ODER VORBEUGUNG VON AORTENANEURYSMEN | [2017/36] | English: | ANTI-IL-1BETA AGENT FOR USE IN THE TREATMENT OR THE PREVENTION OF AORTIC ANEURYSM | [2017/36] | French: | AGENT CONTRE IL-1BETA DESTINÉ À ÊTRE UTILISÉ DANS LE TRAITEMENT OU LA PRÉVENTION D'UN ANÉURISME AORTIQUE | [2017/36] |
| Former [2015/05] | VERFAHREN UND PHARMAZEUTISCHE ZUSAMMENSETZUNG ZUR VERWENDUNG BEI DER BEHANDLUNG ODER VORBEUGUNG VON ANEURYSMEN | ||
| Former [2015/05] | METHOD AND PHARMACEUTICAL COMPOSITION FOR USE IN THE TREATMENT OR THE PREVENTION OF ANEURYSM | ||
| Former [2015/05] | MÉTHODE ET COMPOSITION PHARMACEUTIQUE DESTINÉE À ÊTRE UTILISÉE DANS LE TRAITEMENT OU LA PRÉVENTION D'UN ANÉVRISME | Entry into regional phase | 03.09.2014 | National basic fee paid | 03.09.2014 | Designation fee(s) paid | 03.09.2014 | Examination fee paid | Examination procedure | 03.09.2014 | Amendment by applicant (claims and/or description) | 03.09.2014 | Examination requested [2015/05] | 11.08.2015 | Despatch of a communication from the examining division (Time limit: M06) | 22.02.2016 | Reply to a communication from the examining division | 12.10.2016 | Despatch of a communication from the examining division (Time limit: M06) | 05.04.2017 | Reply to a communication from the examining division | 22.09.2017 | Communication of intention to grant the patent | 03.02.2018 | Application deemed to be withdrawn, date of legal effect [2018/31] | 13.03.2018 | Despatch of communication that the application is deemed to be withdrawn, reason: fee for grant / fee for printing not paid in time [2018/31] | Divisional application(s) | The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is 11.08.2015 | Fees paid | Renewal fee | 24.03.2015 | Renewal fee patent year 03 | 23.03.2016 | Renewal fee patent year 04 | 23.03.2017 | Renewal fee patent year 05 | Penalty fee | Additional fee for renewal fee | 31.03.2018 | 06 M06 Not yet paid |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Cited in | International search | [I] - MORIWAKI TAKUYA ET AL, "Impaired progression of cerebral aneurysms in interleukin-1 beta-deficient mice", STROKE, (200603), vol. 37, no. 3, ISSN 0039-2499, pages 900 - 905, XP009162227 [I] 1-3 * the whole document * * in particular abstract figures * DOI: http://dx.doi.org/10.1161/01.STR.0000204028.39783.d9 | [I] - LEE YOUNGHO ET AL, "Interleukin-1[beta] is crucial for the induction of coronary artery inflammation in a mouse model of Kawasaki disease", CIRCULATION, LIPPINCOT WILLIAMS AND WILKINS, BALTIMORE, US, (20120223), vol. 125, no. 12, ISSN 1524-4539, pages 1542 - 1550, XP009162210 [I] 1-3 * abstract * * published online February 23, 2012 * DOI: http://dx.doi.org/10.1161/CIRCULATIONAHA.111.072769 | [A] - LEI ZHANG ET AL, "Overexpression of interleukin-1 and interferon- in type I thoracic aortic dissections and ascending thoracic aortic aneurysms: possible correlation with matrix metalloproteinase-9 expression and apoptosis of aortic media cells", EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY, SPRINGER VERLAG, BERLIN, DE, vol. 40, no. 1, doi:10.1016/J.EJCTS.2010.09.019, ISSN 1010-7940, (20100905), pages 17 - 22, (20100917), XP028228425 [A] 1-3 * the whole document * DOI: http://dx.doi.org/10.1016/j.ejcts.2010.09.019 | [A] - WANG YU ET AL, "TGF-beta activity protects against inflammatory aortic aneurysm progression and complications in angiotensin II-infused mice", JOURNAL OF CLINICAL INVESTIGATION, (201002), vol. 120, no. 2, ISSN 0021-9738, pages 422 - 432, XP009162240 [A] 1-3 * the whole document * | Examination | - CHURCH LEIGH D ET AL, "Canakinumab: a human anti-IL-1[beta] monoclonal antibody for the treatment of cryopyrin-associated periodic syndromes.", EXPERT REVIEW OF CLINICAL IMMUNOLOGY NOV 2010, (201011), vol. 6, no. 6, ISSN 1744-8409, pages 831 - 841, XP009185686 DOI: http://dx.doi.org/10.1586/eci.10.66 | - HUMPHREY J D ET AL, "Intracranial and abdominal aortic aneurysms: similarities, differences, and need for a new class of computational models.", ANNUAL REVIEW OF BIOMEDICAL ENGINEERING 2008, (2008), vol. 10, ISSN 1523-9829, pages 221 - 246 | - ZAMBROWICZ BRIAN P ET AL, "Knockouts model the 100 best-selling drugs--will they model the next 100?", NATURE REVIEWS. DRUG DISCOVERY JAN 2003, (200301), vol. 2, no. 1, doi:doi:10.1038/nrd987, ISSN 1474-1776, pages 38 - 51, XP002451004 DOI: http://dx.doi.org/10.1038/nrd987 |